Biotest Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 2/6

Biotest şirketinin toplam hissedar öz sermayesi €527.5M ve toplam borcu €613.9M olup, bu da borç-öz sermaye oranını 116.4% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla €1.3B ve €819.2M dir. Biotest 'in FAVÖK'ü €70.0M faiz karşılama oranı 2.2 dur. Şirketin €24.7M tutarında nakit ve kısa vadeli yatırımları bulunmaktadır.

Anahtar bilgiler

116.4%

Borç/özkaynak oranı

€613.90m

Borç

Faiz karşılama oranı	2.2x
Nakit	€24.70m
Eşitlik	€527.50m
Toplam yükümlülükler	€819.20m
Toplam varlıklar	€1.35b

Son finansal sağlık güncellemeleri

Güncelleme yok

Recent updates

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: BIO3 'nin kısa vadeli varlıkları ( €704.5M ) kısa vadeli yükümlülüklerini ( €277.1M ) aşıyor.

Uzun Vadeli Yükümlülükler: BIO3 şirketinin kısa vadeli varlıkları ( €704.5M ) uzun vadeli yükümlülüklerini ( €542.1M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: BIO3 'nin net borç/öz sermaye oranı ( 111.7% ) yüksek olarak değerlendiriliyor.

Borcun Azaltılması: BIO3 şirketinin borç/öz sermaye oranı son 5 yılda 73.4% seviyesinden 116.4% seviyesine yükseldi.

Borç Kapsamı: BIO3 'nin borcu işletme nakit akışı ( 14.6% ) tarafından iyi bir şekilde karşılanmıyor.

Faiz Kapsamı: BIO3 'in borcuna ilişkin faiz ödemeleri EBIT ( 2.2 x kapsam) tarafından iyi karşılanmıyor.

Biotest Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 2/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Recent updates

Third quarter 2024 earnings released

Biotest Aktiengesellschaft to Report Fiscal Year 2024 Results on Mar 28, 2025

Second quarter 2024 earnings released: EPS: €0.24 (vs €0.075 loss in 2Q 2023)

Biotest Aktiengesellschaft to Report Q2, 2024 Results on Aug 06, 2024

Biotest Receives FDA Approval for Innovative Yimmugo Immunoglobulin to Treat Primary Immunodeficiencies

First quarter 2024 earnings released: EPS: €0.74 (vs €0.53 loss in 1Q 2023)

Upcoming dividend of €0.08 per share

New minor risk - Share price stability

New minor risk - Earnings quality

New major risk - Revenue and earnings growth

Biotest Aktiengesellschaft, Annual General Meeting, May 07, 2024

Biotest Aktiengesellschaft to Report First Half, 2024 Results on Jul 30, 2024

Biotest Aktiengesellschaft to Report Fiscal Year 2023 Results on Mar 28, 2024

Third quarter 2023 earnings released

Biotest Aktiengesellschaft Raises Earnings Guidance for the Year 2023

Biotest AG Appoints Peter Janssen as Chairman of the Management Board, Effective from January 1, 2024

New major risk - Financial position

Biotest Treats First Patient with Severe Community- Acquired Pneumonia in Phase III Trial with Trimodulin

Biotest AG Announces US Food and Drug Administration Accepts Marketing Authorization Application for Immunoglobulin Yimmugo

Second quarter 2023 earnings released: EPS: €0.55 (vs €0.39 loss in 2Q 2022)

First quarter 2023 earnings released

Full year 2022 earnings released

Biotest AG Appoints Ainhoa Mendizabal as CFO, with Effect from 15 February, 2023

Biotest Aktiengesellschaft to Report Fiscal Year 2022 Results on Mar 23, 2023

Third quarter 2022 earnings released

No longer forecast to breakeven

Second quarter 2022 earnings released: €0.39 loss per share (vs €0.11 loss in 2Q 2021)

Biotest AG Conducts Clinical Phase III Study PreCyssion with Cmv Hyperimmunoglobulin (Cytotect CP Biotest-) for the Prevention of CMV Infection in the Unborn Child in Germany

Biotest AG Achieves Important Milestone in Phase III Study in Acquired Fibrinogen Deficiency

First quarter 2022 earnings released

Biotest AG Announces Board Changes

Upcoming dividend of €0.04 per share

Grifols, S.A. (BME:GRF) completed the acquisition of a 45.48% stake in Biotest Aktiengesellschaft (XTRA : BIO3) from Tiancheng International Investment Limited.

Biotest Submits Marketing Authorisation Application for IgG Next Generation

Biotest AG Announces Biotest Treats First CMV-Positive Pregnant Woman in Phase III Clinical Trial to Prevent Transmission of CMV Infection to the Unborn Child

Biotest AG Accelerates Trimodulin Development in Hospitalized Covid-19 Patients with Federal Funding from the German Ministries of Health, and Education & Research

Third quarter 2021 earnings released

Forecast to breakeven in 2022

Biotest Receives Approval for Phase III Clinical Trial in Pregnant Women for Prevention of CMV Infection of the Unborn Baby

Biotest Announces the Outcome for Its ESsCOVID (Escape from Severe COVID-19) Trial in Patients with Severe COVID-19

Second quarter 2021 earnings released: €0.11 loss per share (vs €0.16 loss in 2Q 2020)

Biotest AG Provides Earnings Guidance for the Year 2021

Biotest AG Successfully Completes Recruitment for Its Clinical Trial with Trimodulin in Severe Covid-19 Patients

First quarter 2021 earnings released: €0.37 loss per share (vs €0.28 loss in 1Q 2020)

Upcoming dividend of €0.04 per share

Full year 2020 earnings released: €0.80 loss per share (vs €0.13 loss in FY 2019)

Biotest Aktiengesellschaft Provides Earnings Guidance for the Year 2021

Biotest AG Supports Clinical Study with Pentaglobin(R) in Covid-19 at the University Hospital Akh Vienna

Biotest AG Revised Earnings Guidance for the Fiscal Year 2020

New 90-day high: €28.80

Biotest Aktiengesellschaft to Report Fiscal Year 2020 Results on Mar 31, 2021

New 90-day high: €28.70

Biotest Aktiengesellschaft Announces Approval of Biotest Aktiengesellschaft for the Treatment of Severe Bacterial Infections with Concomitant Use of Antibiotics

Biotest Aktiengesellschaft to Report Q1, 2021 Results on May 11, 2021

Third quarter 2020 earnings released: €0.39 loss per share

New 90-day high - €25.30

First half earnings released

New 90-day high - €22.40

New 90-day high - €21.30

Biotest Aktiengesellschaft to Report Q2, 2020 Results on Aug 13, 2020

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Sağlıklı şirketleri keşfedin